Immunogenic treatment of cancer
The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.
1. A method for treating a tumour in a human patient, wherein the tumour is pancreatic cancer, the method comprising:
applying an ablative tumour disruption therapy to the tumour to induce damage to the tumour or one or more tumour cells and release of tumour antigens, wherein the ablative tumour disruption therapy is targeted radiotherapy of the tumour, and wherein the targeted radiotherapy comprises a dose of radiation that is fractionated; and
simultaneously, separately, or sequentially with the induction of damage to the tumour or one or more tumour cells, intradermally administering to the human patient an effective amount of an immunomodulator composition consisting of non-pathogenic heat-killed whole cell Mycobacterium obuense , wherein 0.01 mg to 1 mg of the non-pathogenic heat-killed whole cell Mycobacterium obuense is intradermally administered per dose, wherein the immunomodulator composition is intradermally administered in multiple doses and is intradermally administered prior to and after the ablative tumour disruption therapy, wherein the tumour is thereby regressed or stabilized.
2. The method of claim 1 , wherein the targeted radiotherapy is stereotactic ablative radiotherapy.
3. The method of claim 1 , wherein the administration of the immunomodulator composition occurs in the range of between 4 weeks and 1 week prior to the ablative tumour disruption therapy and is continued after the ablative tumour disruption therapy.
4. The method of claim 1 , wherein the dose of radiation is applied in 3 to 5 fractions.
5. The method of claim 1 , wherein the tumour is metastatic.
6. The method of claim 1 , wherein the effective amount of the immunomodulator composition comprises in the range of 10 3 to 10 11 cells of the non-pathogenic heat-killed whole cell Mycobacterium obuense per dose.
7. A method for treating metastatic pancreatic cancer in a human patient, the method comprising:
applying an ablative disruption therapy to metastatic cancer tissue at a site different to that of a primary pancreatic tumour, wherein the ablative disruption therapy induces damage to the metastatic cancer tissue and release of tumour antigens, wherein the ablative disruption therapy is targeted radiotherapy, and wherein the targeted radiotherapy comprises a dose of radiation that is fractionated; and
simultaneously, separately, or sequentially with the ablative disruption therapy, intradermally administering to the human patient an effective amount of an immunomodulator composition consisting of non-pathogenic heat-killed whole cell Mycobacterium obuense , wherein 0.01 mg to 1 mg of the non-pathogenic heat-killed whole cell Mycobacterium obuense is intradermally administered per dose, wherein the immunomodulator composition is intradermally administered in multiple doses and is intradermally administered prior to and after the ablative disruption therapy, and wherein the primary pancreatic tumour and/or the metastatic cancer tissue is thereby regressed or stabilized.
8. The method of claim 7 , wherein the targeted radiotherapy is stereotactic ablative radiotherapy.
9. A method for treating metastatic pancreatic cancer in a human patient, the method comprising:
applying stereotactic ablative radiotherapy to metastatic cancer tissue at a site different to that of a primary pancreatic tumour, wherein the stereotactic ablative radiotherapy induces damage to the metastatic cancer tissue and release of tumour antigens, and wherein the stereotactic ablative radiotherapy comprises a dose of radiation that is fractionated; and
simultaneously, separately, or sequentially with the stereotactic ablative radiotherapy, intradermally administering to the human patient an effective amount of an immunomodulator composition consisting of non-pathogenic heat-killed whole cell Mycobacterium obuense , wherein 0.01 mg to 1 mg of the non-pathogenic heat-killed whole cell Mycobacterium obuense is intradermally administered per dose, wherein the immunomodulator composition is intradermally administered in multiple doses and is intradermally administered prior to and after the stereotactic ablative radiotherapy, and wherein the primary pancreatic tumour and/or the metastatic cancer tissue is thereby regressed or stabilized.
10. The method of claim 1 , wherein the tumour is thereby regressed, and wherein said method further comprises continuing to intradermally administer the immunomodulator composition after the regression of the tumour.
11. The method of claim 7 , wherein the primary pancreatic tumour and/or the metastatic cancer tissue is thereby regressed, and wherein said method further comprises continuing to intradermally administer the immunomodulator composition after the regression of the primary pancreatic tumour and/or the metastatic cancer tissue.
12. The method of claim 9 , wherein the primary pancreatic tumour and/or the metastatic cancer tissue is thereby regressed, and wherein said method further comprises continuing to intradermally administer the immunomodulator composition after the regression of the primary pancreatic tumour and/or the metastatic cancer tissue.